antiretroviral

Starting Antiretroviral Therapy Can Trigger Leprosy+

20th September 2007
Diana Lockwood
diana lockwood Starting Antiretroviral Therapy Can Trigger Leprosy
Diana Lockwood

REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
DIANA LOCKWOOD, London School of Hygiene and Tropical Medicine
ICAAC delegates heard that ‘hidden’ leprosy can be triggered in some patients who are receiving HIV antiretroviral

…

Read More+

London School of Hygiene & Tropical Medicine Audio News Review, August 31st, 2007+

31st August 2007
philippe mayaud London School of Hygiene & Tropical Medicine Audio News Review, August 31st, 2007
Philippe Mayaud

Herpes Simplex Therapy Reduces HIV Activity in Co-Infected Patients

REFERENCE: N Engl J Med 2007; 356: 790-9
PHILIPPE MAYAUD, London School of Hygiene and Tropical Medicine
It is possible to reduce HIV activity in patients who are co-infected

…

Read More+

Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety+

13th March 2007
howard mayer Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety

mark wainberg Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety

HOWARD MAYER, Pfizer Global Research, New London CT
MARK WAINBERG, McGill University, Montreal

Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007
In a population of treatment-experienced HIV-infected subjects, maraviroc plus optimised background …
Read More+

Entecavir Shows Activity Against HIV But Also Selects for an Antiretroviral Drug Resistance Mutation+

5th March 2007
chloe thio Entecavir Shows Activity Against HIV But Also Selects for an Antiretroviral Drug Resistance Mutation

CHLOE THIO, Johns Hopkins University School of Medicine

REFERENCE: Abstract: 136LB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007
Entecavir, used to treat hepatitis B virus infections, can lower levels of HIV in co-infected patients but …
Read More+

Growth Hormone Releasing Factor Analog: Slimming Aid for Patients Receiving HAART?+

28th February 2007
steven grinspoon Growth Hormone Releasing Factor Analog: Slimming Aid for Patients Receiving HAART?

judith currier Growth Hormone Releasing Factor Analog: Slimming Aid for Patients Receiving HAART?

STEVEN GRINSPOON, Massachusetts General Hospital, Boston
COMMENT: JUDITH CURRIER, University of California, Los Angeles

REFERENCE: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007
Daily administration of an analog of growth hormone releasing factor to HIV patients …
Read More+

Three-Class Antiretroviral Therapy for HIV Not Appropriate: Results from the FIRST Study+

19th January 2007
rodger macarthur Three Class Antiretroviral Therapy for HIV Not Appropriate: Results from the FIRST Study

RODGER MACARTHUR, Wayne State University, Detroit

REFERENCE: Lancet 2006; 368: 2125-35
A three-class HIV antiretroviral therapy is not necessary, according to data published in the Lancet. The FIRST study had three arms which included non-nucleoside reverse transcriptase inhibitors (NNRTIs), …
Read More+

Audio Journal of Global Health Issues: Good Adherence to HIV Antiretroviral Therapy in Rural Uganda+

4th December 2006
paul weidle Audio Journal of Global Health Issues: Good Adherence to HIV Antiretroviral Therapy in Rural Uganda

PAUL WEIDLE, Centers for Disease Control and Prevention, Atlanta

REFERENCE: Lancet 2006; 368:1587-94
In rural sub-Saharan Africa there are many barriers to taking antiretroviral therapy successfully. However, a new study in the Lancet shows that these barriers can be …
Read More+

Reporting from the 2006 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, San Francisco+

30th September 2006
jose miro Reporting from the 2006 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, San Francisco
Jose Miro
julia dombrowski Reporting from the 2006 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, San Francisco
Julia Dombrowski
graeme forrest Reporting from the 2006 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, San Francisco
Graeme Forrest

HIV/AIDS Antiretroviral Therapy: Good to Start when CD4 Count Drops Below 350

REFERENCE: Abstract H-1059
Jose Miro, Hospital Clinic, Barcelona
When is the best time to start antiretroviral therapy for HIV/AIDS? A study from

…

Read More+

Audio Journal of Global Health Issues: Tipranavir Brings Hope for HIV-1 Patients Resistant to Standard Antiretorviral Therapy+

29th September 2006
charles hicks Audio Journal of Global Health Issues: Tipranavir Brings Hope for HIV 1 Patients Resistant to Standard Antiretorviral Therapy

CHARLES HICKS, Associate Professor Medicine, Duke University, Durham

REFERENCE: Lancet 2006; 368: 466-75
Results with a new antiretroviral agent, tipranavir, tested among patients who were resistant to standard therapies have been published in The Lancet. Charles Hicks of Duke University …
Read More+

Delivering Antiretroviral Therapy for HIV/AIDS in Uganda – Challenges and Future Areas of Research+

9th June 2006
andy haines Delivering Antiretroviral Therapy for HIV/AIDS in Uganda – Challenges and Future Areas of Research

Andy Haines, London School of Hygiene and Tropical Medicine

In Sub-Saharan Africa, antiretroviral therapy for HIV/AIDS is becoming more available and more affordable. However, coverage is still far from complete. Andy Haines, director of the London School of Hygiene and …
Read More+